Loading stock data…
ADIL
$1.55+0.01 (+0.65%)
Market ClosedLast close May 1
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adial Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.55. The stock is currently near its 52-week low of $1.51, remaining 76.0% below its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why ADIL maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.55
Potential Upside
5%
Whystock Fair Value$1.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$25.00+1512.9%
Range$8.00 – $42.00
Fundamentals
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-297.46%
Volume
Today's trading volume
61,730
Recent News
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minutes provide the FDA's formal input into the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy. The objective for the EOP2 Meeting was to align with the FDA on the design of the Phase 3 clinical development program for AD04, the company's lead investigational drug, a
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL). Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is […]